High Impact of Oatp1a/1b Transporters on <i>In Vivo</i> Disposition of the Hydrophobic Anticancer Drug Paclitaxel

Evita van de Steeg(Netherlands Organisation for Applied Scientific Research), Alfred H. Schinkel(Oncode Institute), Anita van Esch, Els Wagenaar(The Netherlands Cancer Institute), Cornelia M.M. van der Kruijssen(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Kathryn E. Kenworthy(GlaxoSmithKline (United Kingdom))
Clinical Cancer Research
November 20, 2010
10.1158/1078-0432.ccr-10-1980
Cited by 55

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688